https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49803 38 years (1.34; 1.04–1.73); those with disease duration > 7 years (1.33; 1.01–1.74); those with EDSS score < 6 (1.21; 1.01–1.46) and ≥ 6 (1.93; 1.11–3.34); and patients with no new MRI lesion (1.73; 1.19–2.51). Conclusions: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.]]> Wed 31 May 2023 15:59:42 AEST ]]> Long-term disability trajectories in primary progressive MS patients: a latent class growth analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36042 Wed 29 Jan 2020 16:35:27 AEDT ]]> Risk of secondary progressive multiple sclerosis: a longitudinal study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38068 p <0.001), longer disease duration (HR=1.01, p=0.038), a higher Expanded Disability Status Scale score (HR=1.30, p<0.001), more rapid disability trajectory (HR=2.82, p<0.001) and greater number of relapses in the previous year (HR=1.07, p=0.010) were independently associated with an increased risk of secondary progressive multiple sclerosis. Improving disability (HR=0.62, p=0.039) and disease-modifying therapy exposure (HR=0.71, p=0.007) were associated with a lower risk. Recent cerebral magnetic resonance imaging activity, evidence of spinal cord lesions and oligoclonal bands in the cerebrospinal fluid were not associated with the risk of conversion. Conclusion:Risk of secondary progressive multiple sclerosis increases with age, duration of illness and worsening disability and decreases with improving disability. Therapy may delay the onset of secondary progression.]]> Wed 24 May 2023 12:22:34 AEST ]]> Defining reliable disability outcomes in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22648 Wed 22 May 2019 14:50:34 AEST ]]> Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51652 Wed 13 Sep 2023 10:00:03 AEST ]]> Predictors of disability worsening in clinically isolated syndrome https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28397 Wed 11 Apr 2018 15:14:13 AEST ]]> Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28923 Wed 11 Apr 2018 10:33:05 AEST ]]> The risk of secondary progressive multiple sclerosis is geographically determined but modifiable https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54611 Wed 06 Mar 2024 10:38:32 AEDT ]]> Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45667 Wed 02 Nov 2022 15:59:08 AEDT ]]> Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51272 Tue 29 Aug 2023 15:42:42 AEST ]]> Multiple Sclerosis Relapses Following Cessation of Fingolimod https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53300 Tue 21 Nov 2023 12:02:22 AEDT ]]> Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27384 Tue 13 Oct 2020 19:16:32 AEDT ]]> Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27446 Tue 13 Oct 2020 19:11:18 AEDT ]]> Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49895 Tue 13 Jun 2023 15:49:48 AEST ]]> Comparative effectiveness in multiple sclerosis: A methodological comparison https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51624 Tue 12 Sep 2023 14:37:58 AEST ]]> Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51450 Tue 05 Sep 2023 17:56:18 AEST ]]> A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51433 Tue 05 Sep 2023 17:53:50 AEST ]]> Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51306 Thu 31 Aug 2023 14:27:51 AEST ]]> Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53990 Thu 25 Jan 2024 13:04:15 AEDT ]]> Prediction of multiple sclerosis outcomes when switching to ocrelizumab https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46515 Thu 24 Nov 2022 15:50:23 AEDT ]]> Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52624 Thu 19 Oct 2023 14:15:33 AEDT ]]> Confirmed disability progression as a marker of permanent disability in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52212 88% likely to be sustained (events with score ˃1.5). Conclusions: Clinicodemographic characteristics of 6-month confirmed disability progression events identify those at high risk of sustained long-term disability. This knowledge will allow future trials to better assess the effect of therapy on long-term disability accrual.]]> Thu 05 Oct 2023 10:22:58 AEDT ]]> Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33303 Thu 04 Oct 2018 16:49:43 AEST ]]> Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41240 Sat 30 Jul 2022 12:19:30 AEST ]]> Fingolimod after natalizumab and the risk of short-term relapse https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20798 Sat 24 Mar 2018 08:05:59 AEDT ]]> Seasonal variation of relapse rate in multiple sclerosis is latitude dependent https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19821 Sat 24 Mar 2018 07:56:56 AEDT ]]> Risk of relapse phenotype recurrence in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20329 Sat 24 Mar 2018 07:55:11 AEDT ]]> Sex as a determinant of relapse incidence and progressive course of multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28805 P < 10−12). However, the female-to-male ratio in patients with relapse-onset multiple sclerosis and zero relapses in any given year was double that of the patients with primary progressive multiple sclerosis. Patient age was a more important determinant of decline in relapse incidence than disease duration (P < 10−12). Females are predisposed to higher relapse activity than males. However, this difference does not explain the markedly lower female-to-male sex ratio in primary progressive multiple sclerosis. Decline in relapse activity over time is more closely related to patient age than disease duration.]]> Sat 24 Mar 2018 07:38:27 AEDT ]]> Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30101 Sat 24 Mar 2018 07:37:59 AEDT ]]> Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29942 -23). A reciprocal relationship was seen for ambient ultraviolet radiation (UVR), with a significantly increasing AAO for patients with MS per each quartile increment of ambient UVR (p=1.56×10-17). We found that the AAO of female patients was ~5 months earlier than male patients (p=0.002). AAO of progressive-onset patients with MS were ~9 years later than relapsing-onset patients (p=1.40×10-265). Conclusions: An earlier AAO in higher latitude regions was found in this worldwide European-descent cohort and correlated inversely with variation in latitudinal UVR. These results suggest that environmental factors which act at the population level may significantly influence disease severity characteristics in genetically susceptible populations.]]> Sat 24 Mar 2018 07:31:01 AEDT ]]> The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23959 Sat 24 Mar 2018 07:10:07 AEDT ]]> Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37732 p = 0.001), brainstem onset (HR = 0.45, p = 0.009), azathioprine (HR = 0.46, p <0.001) and mycophenolate mofetil (HR = 0.09, p = 0.012) were associated with a reduced risk of relapse. A greater EDSS was associated with age (β = 0.45 (per decade), p<0.001) and disease duration (β = 0.07 per year, p <0.001). A slower increase in EDSS was associated with azathioprine (β = -0.48, p <0.001), mycophenolate mofetil (β = -0.69, p = 0.04) and rituximab (β = -0.35, p = 0.024). Interpretation: This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.]]> Mon 29 Mar 2021 13:09:59 AEDT ]]> Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48109 Mon 27 Feb 2023 15:22:15 AEDT ]]> Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51965 Mon 25 Sep 2023 08:53:21 AEST ]]> Association of inflammation and disability accrual in patients with progressive-onset multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36719 Mon 24 Aug 2020 10:45:35 AEST ]]> Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41847 p = 0.010); but no differences in spontaneous abortions, term or preterm births. Conclusions: We report low pregnancy incidence rates, with increasing number of pregnancies conceived on DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively short at one month.]]> Mon 15 Aug 2022 10:27:59 AEST ]]> Predictors of treatment switching in the Big Multiple Sclerosis Data Network https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54767 Mon 11 Mar 2024 15:00:30 AEDT ]]> Defining secondary progressive multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25306 Mon 06 Mar 2023 17:55:37 AEDT ]]> Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41309 Mon 01 Aug 2022 12:30:36 AEST ]]> Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46553 Fri 25 Nov 2022 11:33:34 AEDT ]]> Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51882 Fri 22 Sep 2023 09:08:11 AEST ]]> Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53931 Fri 22 Mar 2024 08:23:10 AEDT ]]> Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53317 Fri 19 Jan 2024 14:25:45 AEDT ]]> Contribution of different relapse phenotypes to disability in multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34630 Fri 05 Apr 2019 11:37:25 AEDT ]]> Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51340 Fri 01 Sep 2023 13:35:50 AEST ]]> Towards personalized therapy for multiple sclerosis: prediction of individual treatment response https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34026 80%) for relapse incidence during the first year and for disability outcomes, moderate for relapse incidence in Years 2–4 and for the change in the cumulative disease burden, and low for conversion to secondary progressive disease and treatment discontinuation. External validation showed similar results, demonstrating high external validity for disability and relapse outcomes, moderate external validity for cumulative disease burden and low external validity for conversion to secondary progressive disease and treatment discontinuation. We conclude that demographic, clinical and paraclinical information helps predict individual response to disease-modifying therapies at the time of their commencement.]]> Fri 01 Feb 2019 10:45:46 AEDT ]]>